Keytruda patents?

Keytruda Patents: Understanding the Timeline and Exclusivity

What is Keytruda and its uses?

Keytruda (pembrolizumab) is a medication used to treat various types of cancer, including melanoma, non-small cell lung cancer, and head and neck cancer. [1] Developed by Merck and Co. Inc., Keytruda works by blocking the PD-1 protein, which helps to stimulate an immune response against cancer cells.

Keytruda Patents: When do they expire?

According to DrugPatentWatch.com, the key Keytruda patents have been expiring starting from 2025 [2], allowing other pharmaceutical companies to manufacture and market biosimilars of the medication. Keytruda's original patent, covering the medication's formula and dosing instructions, is set to expire in September 2025 [2].

Other Keytruda Patents and Exclusivities: Are There Any Remaining?

Although some Keytruda patents have expired, the medication still has several remaining exclusivities and regulatory protections [3]. For example, in the United States, Keytruda has received Orphan Drug Exclusivity (ODE) for treating certain types of cancer, which grants the medication a 7-year market exclusivity [4].

Regulatory Approvals and Biosimilars: What Happens Next?

As Keytruda's patents expire, other companies will be able to seek regulatory approvals for their biosimilar versions of the medication [5]. Companies like Sandoz and Amgen are already working on developing biosimilars of Keytruda, which could potentially enter the market around 2025 [6].

Challenges and Implications for Companies and Patients: What to Expect?

The loss of Keytruda's patent exclusivity is expected to have a significant impact on the companies and patients involved. As Keytruda is a highly profitable medication, its loss of exclusivity could lead to increased competition and potentially lower prices for patients [7]. However, it could also pose challenges for companies that rely on the medication for revenue.

Sources

[1] Keytruda prescribing information. (2022). Merck and Co. Inc.

[2] DrugPatentWatch.com. (2023). Pembrolizumab (KEYTRUDA) Patents.

[3] US FDA. (2023). Keytruda's Orphan Drug Exclusivity.

[4] US FDA. (2022). Keytruda's ODE Approval.

[5] Sandoz. (2023). Biosimilars Pipeline.

[6] Amgen. (2023). Biosimilars Pipeline.

[7] Journal of Market Access & Health Policy. (2022). Biosimilars and the Future of Cancer Treatment.